Brugada Syndrome

Subscribe to Selected New Research on Brugada Syndrome

338 relevant articles (9 outcomes, 24 trials/studies) found for this Disease

Description: An autosomal dominant defect of cardiac conduction that is characterized by an abnormal ST-segment in leads V1-V3 on the ELECTROCARDIOGRAM resembling a right BUNDLE-BRANCH BLOCK, high risk of VENTRICULAR TACHYCARDIA or VENTRICULAR FIBRILLATION, SYNCOPAL EPISODE, and possible sudden death. This syndrome is linked to mutations of gene encoding the cardiac SODIUM CHANNEL alpha subunit.

Also Known As:

Brugada ECG Pattern; Brugada Type ECG Pattern; Sudden Unexplained Nocturnal Death Syndrome (SUNDS); ECG Pattern, Brugada

Relationship Network

Disease Context: Research Results

Cardiovascular Diseases: 18449

Heart Diseases: 12331

Cardiac Arrhythmias: 8618

Brugada Syndrome: 338

Congenital, Hereditary, and Neonatal Diseases and Abnormalities: 420

Inborn Genetic Diseases: 548

Brugada Syndrome: 338

Related Diseases

1.	Syndrome
2.	Sudden Death
3.	Ventricular Tachycardia
4.	Ventricular Fibrillation
5.	Pain (Aches)

Experts

1.	Antzelevitch, Charles: 9 articles (08/2008 - 11/2002)
2.	Wilde, Arthur A M: 6 articles (06/2008 - 06/2005)
3.	Aizawa, Yoshifusa: 6 articles (06/2008 - 11/2004)
4.	Hiraoka, Masayasu: 6 articles (05/2008 - 02/2002)
5.	Sakurada, Harumizu: 6 articles (05/2008 - 02/2002)
6.	Brugada, Pedro: 6 articles (02/2007 - 09/2002)
7.	Brugada, Ramon: 5 articles (08/2008 - 11/2004)
8.	Dumaine, Robert: 5 articles (08/2008 - 11/2004)
9.	Chinushi, Masaomi: 5 articles (05/2007 - 11/2004)
10.	Bezzina, Connie R: 4 articles (06/2008 - 06/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Brugada Syndrome:

1.	Anti-Arrhythmia AgentsIBA 10/01/1999 - "We sought to study the long-term value of electrophysiologic (EP)-guided therapy with Class IA antiarrhythmic drugs in patients with idiopathic VF with or without the Brugada syndrome" 02/01/2008 - "CONCLUSIONS: Because of the concerns of proarrhythmias with antiarrhythmic drugs, PVI may be an effective strategy for highly symptomatic patients with AF who have a Brugada ECG pattern." 05/01/2007 - "BACKGROUND: In patients with Brugada syndrome, class I antiarrhythmic drugs can trigger ventricular arrhythmias (VA)" 04/01/2006 - "In particularly, portable ECG is useful for noncontinual ECG monitoring of patients with Brugada syndrome and those administered with antiarrhythmic drugs" 05/01/2005 - "A novel missense mutation in the SCN5A gene associated with Brugada syndrome bidirectionally affecting blocking actions of antiarrhythmic drugs." Order ALL the reference details at left...
2.	Quinidine (Chinidin)FDA LinkGeneric 09/28/2004 - "Efficacy of quinidine in high-risk patients with Brugada syndrome." 11/01/2007 - "Quinidine has been proved efficient in cases of Brugada syndrome." 01/01/2006 - "This is the first report describing quinidine-induced elimination of the late potential, which is considered one of the parameters for an arrhythmic event, in a patient with Brugada syndrome." 01/01/2006 - "Elimination of late potentials by quinidine in a patient with Brugada syndrome." 07/01/2005 - "This case report, together with few others reported in the literature, suggests a role of oral quinidine in the treatment of electrical storm in Brugada syndrome." Order ALL the reference details at left...
3.	Sodium Channels (Sodium Channel)IBA 11/01/2000 - "Molecular study did not reveal the same mutations in the cardiac sodium channel gene (SCN5A) as previously reported in Brugada syndrome" 04/01/2000 - "OBJECTIVE: In this study we have identified and electrophysiologically characterized, in patients having either LQTS or Brugada syndrome, three mutations in SCN5A (a cardiac sodium channel gene)" 11/01/2008 - "BACKGROUND: Patients with a type 2 or 3 Brugada syndrome (BS) pattern and a negative sodium channel blocker challenge (SCBC) are not considered as affected" 10/01/2008 - "Brugada syndrome is an inherited arrhythmic disorder, and mutations in the SCN5A gene, encoding cardiac sodium channels, are identified in approximately 15% of cases" 08/01/2008 - "Agents including the effect on sodium channel are restricted in patients with Brugada electrocardiogram (ECG) pattern or Brugada syndrome" Order ALL the reference details at left...
4.	Ajmaline (Wolfina)FDA Link 12/01/2007 - "On the basis of electrophysiological study, positive ajmaline test, persistent ST segment elevation in inferior leads and other clinical features (PQ interval of 240 ms, family history of SCD) a diagnosis of variant Brugada syndrome was made" 08/01/2007 - "Ajmaline challenge in Brugada syndrome." 10/01/2006 - "The presence of abnormal repolarization patterns, which in otherwise sporadic individuals might be classified under normal variations, have become a diagnostic challenge for clinicians facing a family with the disease [Hong K, Brugada J, Oliva A, Berruezo-Sanchez A, Potenza D, Pollevick GD, et al. Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations" 06/01/2006 - "These findings indicate that high precordial leads should be routinely recorded while assessing the ajmaline test in patients suspected of having the Brugada syndrome." 06/01/2006 - "Intravenous ajmaline (50 mg) did not elicit the type 1 pattern of the Brugada syndrome in the precordial leads obtained at their usual level, but a clear-cut coved-type repolarization was apparent in high right precordial leads" Order ALL the reference details at left...
5.	Disopyramide (Norpace)FDA LinkGeneric 04/01/1997 - "However, ST-segment elevation and the rSr' pattern in leads V(1-3) characteristic of Brugada syndrome became exaggerated by disopyramide" 04/01/1997 - "Discrepant drug action of disopyramide on ECG abnormalities and induction of ventricular arrhythmias in a patient with Brugada syndrome." 04/01/1997 - "Disopyramide exerted discrepant action on the electrocardiographic (ECG) abnormalities and induction of VF in this patient, suggesting the efficacy of antiarrhythmic drugs assessed by an electrophysiologic study may be unrelated to ECG abnormalities in cases of Brugada syndrome." Order ALL the reference details at left...
6.	Sodium Channel Blockers (Potassium Sparing Diuretics)IBA 01/01/2008 - "Sodium channel blockers enhance the temporal QT interval variability in the right precordial leads in Brugada syndrome." 08/01/2006 - "INTRODUCTION: Provocation tests with sodium channel blockers are often required to unmask ECG abnormalities in Brugada syndrome (BrS)" 01/24/2006 - "The extent of QRS widening during challenge with sodium channel blockers, known to be arrhythmogenic in Brugada syndrome and other settings, was also genotype dependent (P=0.002)" 01/01/2006 - "The ECG manifestations of the Brugada syndrome are often dynamic or concealed and may be revealed or modulated by sodium channel blockers" 10/01/2005 - "In this review, several drugs in addition to sodium-channel blockers and conditions that induce transient ST-segment elevation such as that in the Brugada syndrome, developing acquired forms of the Brugada syndrome, are discussed." Order ALL the reference details at left...
7.	Clonazepam (Rivotril)FDA LinkGeneric 08/01/2008 - "After recommended therapies without sodium channel blocking effect were failed in a 40-year-old male with CH whose ECG shows Brugada ECG pattern, clonazepam and codein phosphate, which are exceptional treatments for CH, were effective for severe unilateral orbital pain." Order ALL the reference details at left...
8.	Flecainide (Tambocor)FDA LinkGeneric 01/01/2003 - "This study shows a high flecainide reproducibility, supporting its diagnostic value in Brugada syndrome" 04/01/2008 - "Specifically, a long QT was absent and a Flecainide challenge for Brugada syndrome was negative" 10/01/2006 - "This report presents two patients with Brugada syndrome with positive flecainide response which was not reproducible in a subsequent test." 10/01/2006 - "Negative flecainide test in Brugada syndrome patients with previous positive response." 08/01/2006 - "Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome." Order ALL the reference details at left...
9.	Norepinephrine (Noradrenaline)FDA LinkGeneric 11/09/2004 - "CONCLUSIONS: The present study on autonomic innervation in Brugada syndrome describes an enhanced presynaptic norepinephrine recycling with preserved beta-adrenoceptor density, further supporting the hypothesis of an autonomic dysfunction in Brugada syndrome" 11/09/2004 - "Presynaptic sympathetic norepinephrine recycling, assessed by 11C-HED, was globally increased in patients with Brugada syndrome compared with a group of age-matched healthy control subjects (92.9+/-16.2 mL/g versus 69.1+/-14.2 mL/g; P<0.05), whereas postsynaptic beta-adrenoceptor density, assessed by 11C-CGP, was similar in patients and control subjects (10.4+/-6.7 pmol/g versus 10.2+/-2.9 pmol/g; P=NS)" 11/09/2004 - "Abnormal myocardial presynaptic norepinephrine recycling in patients with Brugada syndrome." 02/12/2002 - "METHODS AND RESULTS: This study investigated the presynaptic cardiac neuronal reuptake of norepinephrine (uptake 1) in 17 patients with Brugada syndrome and 10 age-matched control subjects with the use of the norepinephrine analogue [123I]m-iodobenzylguanidine (123I-MIBG), single-photon emission CT (SPECT), and quantitative 33-segment bull's-eye analysis" Order ALL the reference details at left...
10.	Isoproterenol (Isoprenaline)FDA LinkGeneric 12/01/2002 - "In this study, the LP from signal-averaged electrocardiography during isoproterenol (ISP) administration in patients with Brugada syndrome is discussed" 11/01/2008 - "Subsequent intravenous infusion of isoproterenol rapidly resolved ST segment elevation, suggesting Brugada syndrome" 06/01/2004 - "METHODS: To clarify their characteristics and mechanisms, body surface maps (BSM) were recorded from patients with the Brugada syndrome (13 cases; a mean age of 48 years) before and after administration of isoproterenol (ISP) or Na channel blockers (12 cases)" 06/01/2004 - "Changes in body surface potential distributions induced by isoproterenol and Na channel blockers in patients with the Brugada syndrome." 03/01/2004 - "Electrical storm in Brugada syndrome successfully treated using isoprenaline." Order ALL the reference details at left...

Therapies and Procedures

1.	Defibrillators (Defibrillator) 03/21/2006 - "CONCLUSIONS: Our data suggest that dmLSB is effective in eliminating the arrhythmogenic substrate responsible for the Brugada syndrome and that it deserves further study as a pharmacological adjunct to implanted cardioverter/defibrillator usage." 06/01/2008 - "Outcome after implantation of cardioverter defibrillator [corrected] in patients with Brugada syndrome: a multicenter Israeli study (ISRABRU)." 04/01/2008 - "T-wave oversensing during exercise one year after cardioverter defibrillator implantation for Brugada syndrome." 01/01/2008 - "Because a defibrillator is the only available therapeutic option at present in Brugada syndrome, physicians will be faced with extremely difficult therapeutic decisions that also have important legal, social and ethical implications, especially in children" 12/01/2007 - "As there is no reliable medical treatment, implantation of a cardioverter defibrillator is indicated in patients with Brugada syndrome, and observation alone in those with Brugada type ECG." Order ALL the reference details at left...
2.	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 09/28/2004 - "BACKGROUND: Automatic implantable cardioverter-defibrillator therapy is considered the only effective treatment for high-risk patients with Brugada syndrome" 01/01/2006 - "Electrophysiological study revealed Brugada syndrome, and an implantable cardioverter defibrillator was placed" 01/01/2005 - "OBJECTIVE: Clinical observation of electrophysiological study and implantable cardioverter defibrillator (ICD) therapy in patients with Brugada syndrome" 01/01/2005 - "The electrophysiological study and implantable cardioverter defibrillator therapy for the patients with Brugada syndrome]" 03/25/2008 - "Atrial arrhythmias are an important cause of inappropriate discharge of implantable defibrillators in patients with Brugada syndrome" Order ALL the reference details at left...
3.	Drug Therapy (Chemotherapy) 10/01/2005 - "Drug therapy in Brugada syndrome." 01/01/2004 - "Role of pharmacotherapy in Brugada syndrome." 08/01/2007 - "We present a case report which illustrates two important principles regarding Brugada syndrome, the dynamic ECG manifestations and the elimination of confounding variables (in this case significant coronary artery disease and cholinergic pharmacotherapy) prior to definitive diagnosis." 08/01/2007 - "Brugada syndrome in the presence of coronary artery disease and parasympathomimetic drug therapy." 06/01/2004 - "A 74-year-old male was found to be suffering from the Brugada syndrome after undergoing high dose chemotherapy followed by autologous peripheral blood stem cell transplantation (ABSCT) for acute myeloid leukemia" Order ALL the reference details at left...
4.	General Anesthesia 04/01/2008 - "Few data are available about patients with Brugada syndrome undergoing major surgery and requiring general anesthesia" 04/01/2008 - "Intra day ECG variation after general anesthesia in Brugada syndrome." 04/01/2005 - "General anesthesia for patients with Brugada syndrome" 08/01/2000 - "We managed a 47-year-old man with Brugada syndrome, who underwent hemilaminectomy under general anesthesia, without untoward cardiovascular events" 08/01/1998 - "We describe a patient with a tentative diagnosis of Brugada syndrome who was given general anesthesia without complications" Order ALL the reference details at left...
5.	Anesthesia 09/01/2006 - "Anesthesia unmasked Brugada syndrome." 05/01/2004 - "We describe 4 patients with suspected Brugada syndrome (only one was confirmed) during genera anesthesia and propose an anesthesiologic management during operation and for the postoperative period (36 hours)." 08/01/1998 - "Brugada syndrome and anesthesia" 04/01/2005 - "CONCLUSION: By avoiding agents or conditions that may exacerbate Brugada syndrome during anesthesia, we were able to manage the patients uneventfully for implantation of a cardioverter-defibrillator." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Brugada Syndrome

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 9 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>